Developer docs
API playgroundTry for free, no card

Search company profiles

CardiaTec Biosciences

Full company profile

uuid00021vo

Namestring
CardiaTec Biosciences
Websiteurl
cardiatec.ai
Company typeenum
Private
Founded yearint
2022
Descriptiontext

CardiaTec Biosciences is a Cambridge-based, Cambridge University spinout digital biotechnology company founded in 2021–2022 that applies artificial intelligence and machine learning to cardiovascular drug discovery. The company's core product is a computational multi-omics platform that ingests and analyzes large-scale biological datasets — including genomics, proteomics, and metabolomics — derived from human heart tissue samples, with the goal of identifying novel therapeutic targets for cardiovascular disease. To feed this platform, CardiaTec has established data-acquisition collaborations with hospitals in the United States and United Kingdom, building what it describes as an extensive proprietary dataset from human cardiovascular tissue that is intended to function as a durable data advantage over generic AI-bio approaches.

The company's business model is structured as a B2B biotech platform: it discovers and validates novel cardiovascular therapeutic targets internally, with the intention of out-licensing or partnering those targets with larger pharmaceutical and biotechnology companies for downstream development and commercialization. Revenue mechanics, when they materialize, are expected to flow from licensing deals, milestone payments, and royalties — there are no published product prices, no named paying customers, and no disclosed commercial agreements at present. CardiaTec is a preclinical-stage venture and currently operates as a private, venture-backed company.

To date, CardiaTec has raised approximately £1.4 million in pre-seed funding (July 2022) and $6.5 million in seed funding (September 2024), for cumulative capital of roughly $8.2 million. The investor base spans Laidlaw Scholars Ventures, APEX Ventures, Montage Ventures, Continuum Health Ventures, Panacea Capital, O2h Ventures, Crista Galli Ventures, and University of Cambridge Enterprise. The company operates from Cambridge, UK, with a headcount of 11–50 employees and a development timeline of under two years from founding to seed close. Marketing and distribution occur through industry conferences, academic channels, and direct enterprise engagement with pharmaceutical partners rather than through conventional product-led channels.

Short descriptiontext

CardiaTec Biosciences is a Cambridge University spinout applying AI and multi-omics analysis of human heart tissue to discover novel cardiovascular drug targets for out-licensing to pharmaceutical and biotechnology partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular drug discovery, multi-omics analysis, AI drug discovery, computational biology, therapeutic target identification
Industry2 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-driven Cardiovascular Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Target Discovery & Licensing
TypeLicensing Royalties
Description

The company discovers novel therapeutic targets for cardiovascular diseases through its computational platform. These targets can be out-licensed to pharmaceutical companies for further development and commercialization, generating milestone payments and royalties.

techcrunch.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

CardiaTec Biosciences operates a computational drug discovery platform that applies AI and machine learning to large-scale multi-omics data derived from human heart tissue to identify and validate novel therapeutic targets for cardiovascular disease. These targets are out-licensed or partnered with pharmaceutical and biotech companies for further development and commercialization.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CardiaTec Biosciences operates a unified computational platform for multi-omics analysis focused on cardiovascular drug discovery. The platform processes large-scale biological data from human heart tissues to uncover novel therapeutic targets and advance AI-driven treatment development. The company collaborates with hospitals in the US and UK to obtain multiomic data for its analysis.

Product and service1 record
1Computational Multi-omics Drug Discovery Platform
CategoryDrug Discovery Platform
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1US and UK Hospitals
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborating with hospitals in the United States and United Kingdom to access human heart tissue samples for multi-omics data analysis. These partnerships provide the biological data necessary to build the company's proprietary cardiovascular database for drug discovery.

techfundingnews.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Isomorphic Labs
TypeBroad incumbent
Description

Alphabet's AI drug discovery subsidiary applying deep learning to biology. Comparable AI-first drug discovery platform with strong computational biology capabilities, though backed by significantly greater resources and broader therapeutic scope.

TypeDirect peer
Description

Iambic (formerly Entos) combines AI-driven platform chemistry with computational biology for drug discovery. Similar preclinical, platform-based AI discovery approach with target ID and lead generation capabilities aimed at pharma partnerships.

TypeEmerging player
Description

Standigm is an AI-driven drug discovery company applying proprietary AI workflows to identify novel targets and candidates. Comparable platform-based AI discovery approach aimed at pharma partnerships, though broader in therapeutic scope.

TypeEmerging player
Description

Owkin applies AI to biological and clinical data for drug discovery and development. Comparable in using AI to mine large biomedical datasets for novel therapeutic insights, with hospital and academic data partnerships similar to CardiaTec's tissue sourcing model.

TypeDirect peer
Description

Insitro applies machine learning to large-scale biological data for drug discovery, with a similar platform model combining proprietary datasets and AI. Both companies leverage multi-omic and cellular data to identify therapeutic targets and partner with larger pharma for development.

TypeBroad incumbent
Description

Recursion is a leading AI-driven drug discovery platform combining high-throughput biology with machine learning across multiple therapeutic areas. Directly comparable to CardiaTec in applying AI/ML to biological data for novel target identification, though operating at much greater scale and across broader indications.

TypeDirect peer
Description

Exscientia (now operating under Recursion) was a pioneer in AI-driven drug design and target identification with pharma partnerships. Comparable platform-based AI discovery model focused on generating novel targets and candidates for out-licensing.

TypeDirect peer
Description

BenevolentAI uses AI to mine biomedical knowledge and identify novel drug targets, with a similar target-discovery and partnership-based business model. Comparable in being a European-headquartered AI drug discovery platform pursuing licensing economics with pharma.

TypeEmerging player
Description

Tenaya is a clinical-stage biotech focused on cardiovascular disease therapeutics. Comparable through the cardiovascular therapeutic focus and reliance on advanced biological platforms to identify novel cardiac targets.

TypeEmerging player
Description

Cardior is a European biotech focused on RNA-based therapeutics for cardiovascular disease. Comparable through dedicated cardiovascular therapeutic focus and use of advanced biological platforms, though focused on a different therapeutic modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CardiaTec Biosciences

AI-driven Cardiovascular Drug Discoverycardiatec.ai

CardiaTec Biosciences is a Cambridge University spinout applying AI and multi-omics analysis of human heart tissue to discover novel cardiovascular drug targets for out-licensing to pharmaceutical and biotechnology partners.

What CardiaTec Biosciences does

CardiaTec Biosciences is a Cambridge-based, Cambridge University spinout digital biotechnology company founded in 2021–2022 that applies artificial intelligence and machine learning to cardiovascular drug discovery. The company's core product is a computational multi-omics platform that ingests and analyzes large-scale biological datasets — including genomics, proteomics, and metabolomics — derived from human heart tissue samples, with the goal of identifying novel therapeutic targets for cardiovascular disease. To feed this platform, CardiaTec has established data-acquisition collaborations with hospitals in the United States and United Kingdom, building what it describes as an extensive proprietary dataset from human cardiovascular tissue that is intended to function as a durable data advantage over generic AI-bio approaches.

The company's business model is structured as a B2B biotech platform: it discovers and validates novel cardiovascular therapeutic targets internally, with the intention of out-licensing or partnering those targets with larger pharmaceutical and biotechnology companies for downstream development and commercialization. Revenue mechanics, when they materialize, are expected to flow from licensing deals, milestone payments, and royalties — there are no published product prices, no named paying customers, and no disclosed commercial agreements at present. CardiaTec is a preclinical-stage venture and currently operates as a private, venture-backed company.

To date, CardiaTec has raised approximately £1.4 million in pre-seed funding (July 2022) and $6.5 million in seed funding (September 2024), for cumulative capital of roughly $8.2 million. The investor base spans Laidlaw Scholars Ventures, APEX Ventures, Montage Ventures, Continuum Health Ventures, Panacea Capital, O2h Ventures, Crista Galli Ventures, and University of Cambridge Enterprise. The company operates from Cambridge, UK, with a headcount of 11–50 employees and a development timeline of under two years from founding to seed close. Marketing and distribution occur through industry conferences, academic channels, and direct enterprise engagement with pharmaceutical partners rather than through conventional product-led channels.

CardiaTec Biosciences firmographics

Firmographics
Name
CardiaTec Biosciences
Website
https://cardiatec.ai
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
CardiaTec Biosciences is a Cambridge University spinout applying AI and multi-omics analysis of human heart tissue to discover novel cardiovascular drug targets for out-licensing to pharmaceutical and biotechnology partners.
Ownership category
akta.pro rank

CardiaTec Biosciences industry classification

Industry
Product category
AI-driven Cardiovascular Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Cardiovascular drug discovery
  • Multi-omics analysis
  • AI drug discovery
  • Computational biology
  • Therapeutic target identification

Where CardiaTec Biosciences is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

CardiaTec Biosciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Drug Target Discovery & Licensing: The company discovers novel therapeutic targets for cardiovascular diseases through its computational platform. These targets can be out-licensed to pharmaceutical companies for further development and commercialization, generating milestone payments and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

CardiaTec Biosciences product offering

Product offering

Core offering

CardiaTec Biosciences operates a computational drug discovery platform that applies AI and machine learning to large-scale multi-omics data derived from human heart tissue to identify and validate novel therapeutic targets for cardiovascular disease. These targets are out-licensed or partnered with pharmaceutical and biotech companies for further development and commercialization.

Product overview

CardiaTec Biosciences operates a unified computational platform for multi-omics analysis focused on cardiovascular drug discovery. The platform processes large-scale biological data from human heart tissues to uncover novel therapeutic targets and advance AI-driven treatment development. The company collaborates with hospitals in the US and UK to obtain multiomic data for its analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • Computational Multi-omics Drug Discovery Platform

Companies that use CardiaTec Biosciences

Customer profile

Segments1 record

Ideal customer profiles1 record

CardiaTec Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

CardiaTec Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • US and UK HospitalscoreStrategic or Co-development PartnerCollaborating with hospitals in the United States and United Kingdom to access human heart tissue samples for multi-omics data analysis. These partnerships provide the biological data necessary to build the company's proprietary cardiovascular database for drug discovery.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

CardiaTec Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Isomorphic Labs: Alphabet's AI drug discovery subsidiary applying deep learning to biology. Comparable AI-first drug discovery platform with strong computational biology capabilities, though backed by significantly greater resources and broader therapeutic scope.
  • Recursion Pharmaceuticals: Recursion is a leading AI-driven drug discovery platform combining high-throughput biology with machine learning across multiple therapeutic areas. Directly comparable to CardiaTec in applying AI/ML to biological data for novel target identification, though operating at much greater scale and across broader indications.

Direct peers

  • Iambic Therapeutics: Iambic (formerly Entos) combines AI-driven platform chemistry with computational biology for drug discovery. Similar preclinical, platform-based AI discovery approach with target ID and lead generation capabilities aimed at pharma partnerships.
  • Insitro: Insitro applies machine learning to large-scale biological data for drug discovery, with a similar platform model combining proprietary datasets and AI. Both companies leverage multi-omic and cellular data to identify therapeutic targets and partner with larger pharma for development.
  • Exscientia: Exscientia (now operating under Recursion) was a pioneer in AI-driven drug design and target identification with pharma partnerships. Comparable platform-based AI discovery model focused on generating novel targets and candidates for out-licensing.
  • BenevolentAI: BenevolentAI uses AI to mine biomedical knowledge and identify novel drug targets, with a similar target-discovery and partnership-based business model. Comparable in being a European-headquartered AI drug discovery platform pursuing licensing economics with pharma.

Emerging players

  • Standigm: Standigm is an AI-driven drug discovery company applying proprietary AI workflows to identify novel targets and candidates. Comparable platform-based AI discovery approach aimed at pharma partnerships, though broader in therapeutic scope.
  • Owkin: Owkin applies AI to biological and clinical data for drug discovery and development. Comparable in using AI to mine large biomedical datasets for novel therapeutic insights, with hospital and academic data partnerships similar to CardiaTec's tissue sourcing model.
  • Tenaya Therapeutics: Tenaya is a clinical-stage biotech focused on cardiovascular disease therapeutics. Comparable through the cardiovascular therapeutic focus and reliance on advanced biological platforms to identify novel cardiac targets.
  • Cardior Pharmaceuticals: Cardior is a European biotech focused on RNA-based therapeutics for cardiovascular disease. Comparable through dedicated cardiovascular therapeutic focus and use of advanced biological platforms, though focused on a different therapeutic modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

CardiaTec Biosciences social profiles

Digital presence

CardiaTec Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CardiaTec Biosciences leadership team

Management profile

Number of profiles

Profiles1 record

CardiaTec Biosciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CardiaTec Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CardiaTec Biosciences

What does CardiaTec Biosciences do?

CardiaTec Biosciences operates a computational drug discovery platform that applies AI and machine learning to large-scale multi-omics data derived from human heart tissue to identify and validate novel therapeutic targets for cardiovascular disease. These targets are out-licensed or partnered with pharmaceutical and biotech companies for further development and commercialization.

Is CardiaTec Biosciences a public or private company?

CardiaTec Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was CardiaTec Biosciences founded?

CardiaTec Biosciences was founded in 2022. It employs 11 to 50 people.

Where is CardiaTec Biosciences based?

CardiaTec Biosciences is headquartered in Cambridge, United Kingdom, in the Europe region.

How does CardiaTec Biosciences make money?

One revenue line is on record: drug Target Discovery & Licensing.

Who are CardiaTec Biosciences's main competitors?

Broad incumbents on record are Isomorphic Labs and Recursion Pharmaceuticals. Direct peers are Iambic Therapeutics, Insitro, Exscientia and BenevolentAI. Emerging players are Standigm, Owkin, Tenaya Therapeutics and Cardior Pharmaceuticals.

Does CardiaTec Biosciences have an API?

No public API is recorded for CardiaTec Biosciences.

What industry is CardiaTec Biosciences in?

CardiaTec Biosciences's product category is AI-driven Cardiovascular Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CardiatecMartyna Cecula, Author at Cardiatec BioSciencesCardiaTec, a Cambridge-based company, was featured in TechRound 11's list of top 10 startups in Cambridge in April 2024. It also joined the BioIndustry Association's Data, AI and Multiomics Advisory Committee, was shortlisted as a finalist for the Cambridge Independent AI Company of the Year Award in March 2025, and was named among the top 100 AI start-ups of 2025.LinkedInCardiaTec BioCardiaTec Biosciences scientist WooChang Hwang is scheduled to speak at the December AI Club event on 4 December at 5:15 pm at the Jeffrey Cheah Biomedical Centre, presenting how the company uses AI and multi-omics data to find cardiovascular disease targets. He previously worked at the Milner Therapeutics Institute and holds a Ph.D. in Bio and Brain Engineering from KAIST.BusinessCloudCardiaTec bags £5m to decode biology of cardiovascular diseaseCardiaTec raised £5 million in seed funding led by Montage Ventures to decode cardiovascular disease biology. The company is building the first and largest human heart tissue-multi-omics dataset from 65 hospitals. Funds will expand its platform and progress proprietary drug targets to preclinical stage.LinkedInWhy We Invested: CardiaTec - Pioneering AI-Driven Cardiovascular Drug DiscoveryMontage Ventures disclosed its £5 million seed investment in Cambridge-based CardiaTec, a startup using AI and multi-omics data to discover cardiovascular drug targets. The company has partnered with over 60 hospitals, built a dataset of more than 3 million omics data points, and identified 141 novel coronary artery disease targets, 84% of which were known and clinically successful.LaidlawfoundationCardiaTec Secures $6.5M Seed Funding to Advance Its Multi-omics Drug Discovery Platform for Cardiovascular DiseasesCardiaTec, a Cambridge-based TechBio company using computational methods to decode cardiovascular disease biology, raised $6.5 million in seed funding led by Montage Ventures, with participation from Laidlaw Scholars Ventures, Apex Ventures and Continuum Health Ventures. The company is building a proprietary multi-omics human heart tissue dataset and has over 65 hospitals across the US and UK screening patients. Funds will expand the platform and progress proprietary targets to wet lab validation.Tech.euCardiaTec raises $6.5M Seed for cardiovascular drug discoveryCardiaTec secured $6.5 million in seed funding led by Montage Ventures to expand its platform for cardiovascular drug discovery. The company utilizes a large multi-omics dataset derived from human heart tissue collected via a network of 65 hospitals in the US and the UK to identify novel therapeutic targets.LinkedIn📣 Very Exciting News to Share! 📣 We are thrilled to announce that CardiaTec Biosciences has raised $6.5M in Seed funding, led by San Francisco-based Montage Ventures! 🎉 In less than two years…CardiaTec Biosciences has secured $6.5 million in seed funding led by Montage Ventures to support the development of its computational platform for cardiovascular therapeutic discovery. The company notes that this capital will aid its ongoing progress in analyzing large-scale multiomics data over the past two years.Tech Funding NewsCardiaTec snaps $6.5M seed funding to revolutionise cardiovascular drug discovery — TFNCardiaTec, a Cambridge-based biotech company, has secured $6.5 million in seed funding to enhance its computational drug discovery platform aimed at combating cardiovascular disease. The funding round was led by Montage Ventures and included support from several other investors, allowing CardiaTec to advance its drug discovery initiatives and push novel targets into preclinical development. The company’s innovative approach combines large-scale human multi-omics data to explore insights in cardiovascular disease, which accounts for 17.9 million deaths annually.YahooHeart disease is the world's biggest killer — this Cambridge Uni spinout is using AI to find new treatmentsCardiaTec, a Cambridge University spinout, raised $6.5 million in seed funding to develop AI-driven treatments for cardiovascular disease. The company aims to build a large human heart tissue dataset to identify novel therapeutics, targeting a disease that causes 17.9 million deaths annually.TechCrunchHeart disease is the world’s biggest killer — this Cambridge Uni spinout is using AI to find new treatmentsCardiaTec, a Cambridge University spinout, raised $6.5 million in seed funding to develop AI-driven treatments for cardiovascular disease. The company aims to build a large human heart tissue dataset to identify novel therapeutics, targeting a disease that causes 17.9 million deaths annually.